Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium
Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium Seattle, WA -- (June 7, 2021) Kineta, Inc., a clinical stage biotechnology company focus ...
A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors
Thierry Guillaudeux, PhD, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2021 | April, 2021
Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)
Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR) Safety, tolerability and pharmacokinetic profile established in Phase 1 clinical study ...
Kineta Presenting at Multiple Investor Conferences in March 2021
Kineta Presenting at Multiple Investor Conferences in March 2021 Seattle, WA -- (March 3, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapie ...
Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain
Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain Seattle, WA -- (December 15, 2020) Kineta Inc, through its subsidia ...
Highly Potent Fully Human Anti-VISTA Antibodies Efficiently Abrogate the Interaction of VISTA to Its Putative Receptors at Different pH
Thierry Guillaudeux, PhD, Chief Scientific Officer European Society for Medical Oncology (ESMO) Virtual Congress 2020 | December 9, 2020
Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies
Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies Seattle, WA -- (December 9, 2020) Kineta, Inc., a clinical stage biotechnology company focused o ...
Highly Potent Fully Human anti-VISTA Antibodies A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells
Thierry Guillaudeux, PhD, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting | November 12, 2020
Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies
Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies Preclinical data demonstrates that VISTA is a novel target checkpoint against immunosuppressive ...
Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Special Conference on Tumor Immunology and Immunotherapy
Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Conference on Tumor Immunology and Immunotherapy Seattle, WA -- (October 20, 2020) Kineta, Inc., a clinical stage biotechno ...